Literature DB >> 19793190

Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive.

S Selleng1, B Malowsky, U Strobel, A Wessel, T Ittermann, H-G Wollert, T E Warkentin, A Greinacher.   

Abstract

BACKGROUND: The high frequency of thrombocytopenia in post-cardiac surgery patients makes it challenging to diagnose heparin-induced thrombocytopenia (HIT). Two platelet count profiles are reported as indicating possible HIT in these patients: profile 1 describes a platelet count fall that begins between postoperative days 5 and 10, whereas profile 2 denotes early-onset thrombocytopenia that persists beyond day 5.
OBJECTIVES: To examine how these platelet count profiles correlate with antibody status and HIT post-cardiac surgery.
METHODS: We prospectively screened 581 cardiac surgery patients for heparin-dependent antibodies by platelet factor 4 (PF4)-heparin immunoassay and platelet-activation test, and performed daily platelet counts (until day 10) with 30-day follow-up.
RESULTS: All three patients with platelet count profile 1 tested positive for platelet-activating anti-PF4-heparin IgG antibodies [odds ratio (OR) 521.7, 95% confidence interval (CI) 3.9-34,000, P = 0.002], and were judged to have HIT. In contrast, none of 25 patients with early-onset and persisting thrombocytopenia (profile 2) was judged to have HIT, including five patients testing positive for platelet-activating anti-PF4-heparin IgG antibodies. In these patients, the frequency of heparin-dependent antibodies did not differ from that in non-thrombocytopenic controls, either for anti-PF4-heparin IgG (OR 1.7, 95% CI 0.7-4.1, P = 0.31) or for platelet-activating antibodies (OR 1.9, 95% CI 0.6-5.7, P = 0.20). Multivariate analysis revealed that type of cardiac surgery, but not HIT antibody status, predicted early-onset and persisting thrombocytopenia. Together, these findings show that HIT was uncommon in this study population [overall frequency, 3/581 (0.5%), 95% CI 0.1-1.5%].
CONCLUSIONS: Thrombocytopenia that begins between 5 and 10 days post-cardiac surgery is highly predictive for HIT. In contrast, early-onset and persisting thrombocytopenia is usually caused by non-HIT factors with coinciding heparin-dependent antibody seroconversion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19793190     DOI: 10.1111/j.1538-7836.2009.03626.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  26 in total

1.  Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.

Authors:  Thomas Gremmel; Karin Frühwirth; Christoph W Kopp; Alexandra Kaider; Sabine Steiner; Tamam Bakchoul; Ulrich J H Sachs; Renate Koppensteiner; Simon Panzer
Journal:  Clin Res Cardiol       Date:  2012-01-11       Impact factor: 5.460

2.  Postoperative failure of platelet recovery is an independent risk factor for poor survival in patients with oral and oropharyngeal cancer.

Authors:  Christos Perisanidis; Martina Mittlböck; Alexandra Schoppmann; Gabriela Kornek; Patrick Starlinger; Anton Stift; Edgar Selzer; Christian Schopper; Rolf Ewers
Journal:  Clin Oral Investig       Date:  2012-05-29       Impact factor: 3.573

3.  Platelet Counts and Postoperative Stroke After Coronary Artery Bypass Grafting Surgery.

Authors:  Jörn A Karhausen; Alan M Smeltz; Igor Akushevich; Mary Cooter; Mihai V Podgoreanu; Mark Stafford-Smith; Susan M Martinelli; Manuel L Fontes; Miklos D Kertai
Journal:  Anesth Analg       Date:  2017-10       Impact factor: 5.108

4.  Platelet factor 4/heparin-particle gel immunoassay (PaGIA) is a weak method for heparin-induced thrombocytopenia (HIT) evaluation of post cardio-pulmonary bypass surgery patients.

Authors:  Chezi Ganzel; Jacob Rowe; David Raveh
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

5.  Improved prediction of HIT in the SICU using an improved model of the Warkentin 4-T system: 3-T.

Authors:  Matthew B Bloom; Jeffrey Johnson; Oksana Volod; Ernest Y Lee; Terris White; Daniel R Margulies
Journal:  Am J Surg       Date:  2019-07-29       Impact factor: 2.565

6.  Over-testing for heparin induced thrombocytopenia in hospitalized patients.

Authors:  Shruti Chaturvedi; Ruhail Kohli; Keith McCrae
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

7.  Acute oxygenator failure: a new presentation of heparin-induced thrombocytopenia in a patient undergoing venovenous extracorporeal membrane oxygenation support.

Authors:  Robert A Ratzlaff; Juan G Ripoll; Lena L Kassab; Jose L Diaz-Gomez
Journal:  BMJ Case Rep       Date:  2016-12-16

8.  Prevalence and outcome of heparin-induced thrombocytopenia diagnosed under veno-arterial extracorporeal membrane oxygenation: a retrospective nationwide study.

Authors:  Antoine Kimmoun; Walid Oulehri; Romain Sonneville; Paul-Henri Grisot; Elie Zogheib; Julien Amour; Nadia Aissaoui; Bruno Megarbane; Nicolas Mongardon; Amelie Renou; Matthieu Schmidt; Emmanuel Besnier; Clément Delmas; Geraldine Dessertaine; Catherine Guidon; Nicolas Nesseler; Guylaine Labro; Bertrand Rozec; Marc Pierrot; Julie Helms; David Bougon; Laurent Chardonnal; Anne Medard; Alexandre Ouattara; Nicolas Girerd; Zohra Lamiral; Marc Borie; Nadine Ajzenberg; Bruno Levy
Journal:  Intensive Care Med       Date:  2018-08-22       Impact factor: 17.440

9.  Characterization of hospitalized cardiovascular patients with suspected heparin-induced thrombocytopenia.

Authors:  Felicitas Stoll; Miriel Gödde; Albrecht Leo; Hugo A Katus; Oliver J Müller
Journal:  Clin Cardiol       Date:  2018-12-03       Impact factor: 2.882

10.  Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery.

Authors:  Miklos D Kertai; Shan Zhou; Jörn A Karhausen; Mary Cooter; Edmund Jooste; Yi-Ju Li; William D White; Solomon Aronson; Mihai V Podgoreanu; Jeffrey Gaca; Ian J Welsby; Jerrold H Levy; Mark Stafford-Smith; Joseph P Mathew; Manuel L Fontes
Journal:  Anesthesiology       Date:  2016-02       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.